Midkine Protein Shows Potential to Inhibit Alzheimer's Amyloid Formation

Recent research conducted by scientists at St. Jude Children's Research Hospital has uncovered a promising new role for the protein midkine in the fight against Alzheimer's disease. Published in Nature Structural & Molecular Biology on August 21, 2025, the study reveals that midkine can prevent the growth of amyloid beta assemblies, which are closely associated with the development of Alzheimer's. The team demonstrated that midkine interacts with amyloid beta proteins, inhibiting their ability to stick together and form the toxic plaques characteristic of the disease.

Midkine, a small growth factor abundantly present during embryonic development and involved in cell proliferation, has traditionally been studied in the context of cancer due to its overexpression in various tumors. Its connection to neurodegeneration was less understood until now. In the study, scientists utilized advanced techniques such as fluorescence assays, circular dichroism, electron microscopy, and nuclear magnetic resonance to explore the interaction between midkine and amyloid beta. The findings showed that midkine effectively hampers the elongation and secondary nucleation phases of amyloid beta assembly, thereby reducing the formation of harmful fibrils.

The researchers further confirmed the protective effect of midkine using Alzheimer’s disease mouse models. Mice lacking the midkine gene exhibited increased amyloid beta accumulation, highlighting the protein’s potential to naturally counteract plaque buildup. These insights open new avenues for drug development, aiming to mimic or enhance midkine's interaction with amyloid beta. Future strategies may involve designing small molecules that replicate midkine's activity to prevent or slow down Alzheimer’s pathology.

This groundbreaking discovery positions midkine as a promising biomolecular target for Alzheimer’s treatment, offering hope for interventions that could modify disease progression by controlling amyloid beta aggregation. Continued research aims to better understand the precise mechanism of midkine’s binding to amyloid beta and to develop therapeutic agents that harness this natural protective effect.

Source: https://medicalxpress.com/news/2025-08-midkine-protein-blocks-alzheimer-amyloid.html